Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland - Wikidata - awgldk - TriplyDB

Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland

Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland

http://www.wikidata.org/entity/Q30491702

about

Does Locoregional Chemotherapy Still Matter in the Treatment of Advanced Pelvic Melanoma?

P2860

Q47163375-0F9D51DF-12FC-4380-BBAA-F724A3412585

P2860

Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland

http://www.wikidata.org/entity/Q30491702

description

2017 nî lūn-bûn

@nan

2017 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Multicenter, real-life experie ...... lanoma patients in Switzerland

@ast

Multicenter, real-life experie ...... lanoma patients in Switzerland

@en

type

label

Multicenter, real-life experie ...... lanoma patients in Switzerland

@ast

Multicenter, real-life experie ...... lanoma patients in Switzerland

@en

prefLabel

Multicenter, real-life experie ...... lanoma patients in Switzerland

@ast

Multicenter, real-life experie ...... lanoma patients in Switzerland

@en

P1433

Q30491702-7093C8D6-C1E8-4796-82FF-D03D418A239B

P1476

Q30491702-C9E27405-B5D8-42F6-8AAD-E8FF9A71D3A5

P2093

Q30491702-25050E06-31FC-454C-B1AA-CF53EABA2A5A

Q30491702-2FEDC696-BC52-4CD7-A19F-A4886403C8A4

Q30491702-3255DAC2-435E-46E9-949C-FBA1BA752109

Q30491702-3E29C48C-6CCD-4C26-84E3-F11A837A75B5

Q30491702-82858CF7-65FE-44C4-BEEB-9984C657AD58

Q30491702-94D222F9-2188-4D58-A741-0D0F34FC8B53

Q30491702-C7F16709-0D3D-4E36-A560-599943496020

Q30491702-CDB7DD86-C8AE-443D-945A-2CFB9F7B61FA

Q30491702-D7DBC26C-B6ED-4C67-B7F5-9A70D13BCC9F

Q30491702-DA030FA8-D9D3-4716-A757-9F5ED0C821A9

P2860

Q30491702-025CC06F-F13B-4764-A392-82F87002AEE1

Q30491702-0356650F-8194-4706-9C9D-187E1BF81044

Q30491702-05D198C5-423B-43B0-8BA9-481617A2799A

Q30491702-0C73091F-06A4-4CDD-8FD6-B630E80219CE

Q30491702-0DD7FEF6-7F78-437F-931A-DCEA0F6CF846

Q30491702-1618148E-89B3-4F62-A06F-503ADE3BA28B

Q30491702-16593848-B1EB-456F-985F-C5B0A998A8B7

Q30491702-18D4E008-893F-418F-AFBD-7793EB864EBE

Q30491702-232BA18E-E7B2-4F72-811D-8080E8EA89AE

Q30491702-24859CF6-0495-42FC-9EC9-A65C4D7AD7CC

P304

Q30491702-17F6A7A2-1B85-4D34-908E-9B75A2639898

P31

Q30491702-87E69421-819C-47B2-A246-B1EED96E4DE6

P356

Q30491702-6438A043-44EE-4F69-90BD-E955221A740D

P407

Q30491702-18CBBCD0-84FF-49C2-AA6E-0411C1FA17A8

P433

Q30491702-C9FF784E-5835-465F-9319-DD9841C6681C

P478

Q30491702-4FF790B2-25EA-4FC7-A8A5-34B7D34536E6

P50

Q30491702-0E1F0CEB-5466-4831-959D-953CDCFB43D9

Q30491702-187AEEB8-2699-4E19-AD70-DF359A8A39D9

Q30491702-9A592DED-28B6-4B9E-B52F-2DBE8744E8DD

P577

Q30491702-0AFF79C4-83AD-489C-BCDC-4738338AA577

P698

Q30491702-CA1BA5F9-21F1-4AC8-B163-742ECA28E6F3

P921

Q30491702-D18C2CFA-2740-454E-84C6-AA86BC2F948A

P932

Q30491702-A1FF9C9C-8E52-4FCD-9D43-24CEB0BC02C1

P356

CMR.0000000000000359

P1433

Melanoma Research

P1476

Multicenter, real-life experie ...... lanoma patients in Switzerland

@en

P2093

Anna L Frauchiger

http://www.w3.org/2001/XMLSchema#string

Corina Kaufmann

http://www.w3.org/2001/XMLSchema#string

Joanna Mangana

http://www.w3.org/2001/XMLSchema#string

Olivier Michielin

http://www.w3.org/2001/XMLSchema#string

Reinhard Dummer

http://www.w3.org/2001/XMLSchema#string

Roger von Moos

http://www.w3.org/2001/XMLSchema#string

Simone M Goldinger

http://www.w3.org/2001/XMLSchema#string

Ulrike Held

http://www.w3.org/2001/XMLSchema#string

Valerie C Amann

http://www.w3.org/2001/XMLSchema#string

Viola Stögner

http://www.w3.org/2001/XMLSchema#string

P2860

Recent advances in the treatment of melanoma with BRAF and MEK inhibitors

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Vemurafenib: the first drug approved for BRAF-mutant cancer

Distinct sets of genetic alterations in melanoma

Pembrolizumab versus Ipilimumab in Advanced Melanoma

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

P304

358-368

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/CMR.0000000000000359

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Mitchell P Levesque

P577

2017-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28509765

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

5633326

http://www.w3.org/2001/XMLSchema#string